Presentation Information
[P-52]Afucosylated anti-HIV-1 V3 antibody controls SHIV and heterologous SIV infection via CD8+ T cell immunity
*Tomotaka Okamura1, Takeo Kuwata2, Natsumi Yasaka3, Kenichi Hanaki1, Shuzo Matsushita2, Yasuhiro Yasutomi4 (1. National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Joint Research Center for Human Retrovirus Infection, Kumamoto University, 3. CURED Inc, 4. Division of Vaccinology for Clinical Development, Institute for Vaccine Research and Development (IVReD), Hokkaido University)